Moderna, Inc. (MRNA): who owns it and who trades it
As of Nov 16, 2026, MRNA insiders reported 22 open-market sales worth $81.6M and no purchases in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Stephen Hoge (President), with $45.4M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Moderna
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds and Congress were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MRNA
776 funds and institutions reported MRNA shares worth $22.6B at the end of Q2 2026, about 81% of the company. The largest holder is FMR LLC (Fidelity) with 13.1%.
Funds and institutions (13F) 81%Everyone else 19%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 51.86M | 13.07% | $3.6B | +14% |
| BlackRock, Inc. | 30.60M | 7.71% | $2.1B | +3% |
| Vanguard Capital Management LLC | 23.21M | 5.85% | $1.6B | +1% |
| Capital World Investors | 22.28M | 5.61% | $1.6B | +19% |
| Baillie Gifford & Co | 18.21M | 4.59% | $1.3B | -9% |
| State Street Corp | 15.73M | 3.96% | $1.1B | +6% |
| Vanguard Portfolio Management LLC | 15.58M | 3.93% | $1.1B | -0% |
| Geode Capital Management, LLC | 9.71M | 2.45% | $679M | +3% |
| Morgan Stanley | 9.54M | 2.40% | $668M | +13% |
| Theleme Partners LLP | 8.06M | 2.03% | $564M | +0% |
| Two Sigma Investments, LP | 7.19M | 1.81% | $504M | -21% |
| Invesco Ltd. | 5.78M | 1.46% | $405M | +21% |
| T. Rowe Price Associates | 5.59M | 1.41% | $391M | +657% |
| Charles Schwab Investment Management Inc | 4.84M | 1.22% | $339M | +2% |
| Sixth Street Partners Management Company, L.P. | 4.84M | 1.22% | $339M | – |
| Goldman Sachs Group Inc | 4.67M | 1.18% | $327M | -29% |
| Flagship Pioneering, LLC | 4.63M | 1.17% | $324M | No change |
| UBS Group AG | 4.46M | 1.12% | $313M | +1% |
| BNP Paribas Financial Markets | 4.38M | 1.10% | $307M | +1% |
| Norges Bank | 3.03M | 0.76% | $212M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MRNA insiders reported $0 of open-market purchases and $81.6M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Stephen Hoge | President | Sale plan | 39,145 | $220.72 | $8.6M | Form 4 |
| Oct 14, 2026 | Stephen Hoge | President | Sale plan | 38,774 | $213.47 | $8.3M | Form 4 |
| Oct 14, 2026 | Stephen Hoge | President | Sale plan | 450 | $214.15 | $96.4K | Form 4 |
| Sep 15, 2026 | Stephen Hoge | President | Sale plan | 40,281 | $146.07 | $5.9M | Form 4 |
| Sep 14, 2026 | Stephen Hoge | President | Sale plan | 40,294 | $144.13 | $5.8M | Form 4 |
| Sep 10, 2026 | James M Mock | CFO | Sale plan | 15,000 | $134.49 | $2M | Form 4 |
| Sep 10, 2026 | James M Mock | CFO | Sale plan | 19,836 | $134.49 | $2.7M | Form 4 |
| Sep 1, 2026 | Shannon Thyme Klinger | Chief Legal Officer | Sale plan | 3,471 | $139.95 | $486K | Form 4 |
| Aug 5, 2026 | Stephane Bancel | CEO | Sale plan | 124,838 | $56.96 | $7.1M | Form 4 |
| Aug 5, 2026 | Stephane Bancel | CEO | Sale plan | 187,044 | $58.79 | $11M | Form 4 |
| Aug 5, 2026 | Stephane Bancel | CEO | Sale plan | 147,473 | $56.21 | $8.3M | Form 4 |
| Aug 5, 2026 | Stephane Bancel | CEO | Sale plan | 39,891 | $58.12 | $2.3M | Form 4 |
| Jul 15, 2026 | Stephen Hoge | President | Sale plan | 53,336 | $67.60 | $3.6M | Form 4 |
| Jun 15, 2026 | Stephen Hoge | President | Sale plan | 53,336 | $51.37 | $2.7M | Form 4 |
| Jun 4, 2026 | Shannon Thyme Klinger | Chief Legal Officer | Sale plan | 3,471 | $50.00 | $174K | Form 4 |
| May 21, 2026 | Noubar Afeyan | Director | Sale | 9,263 | $46.84 | $434K | Form 4 |
| May 15, 2026 | Stephen Hoge | President | Sale plan | 53,336 | $48.40 | $2.6M | Form 4 |
| May 1, 2026 | Abbas Hussain | Director | Sale plan | 5,682 | $46.63 | $265K | Form 4 |
| Mar 2, 2026 | Shannon Thyme Klinger | Chief Legal Officer | Sale plan | 13,885 | $52.29 | $726K | Form 4 |
| Feb 23, 2026 | Stephen Hoge | President | Sale plan | 160,009 | $48.84 | $7.8M | Form 4 |
| Dec 11, 2025 | Noubar Afeyan | Director | Sale | 23,853 | $29.49 | $703K | Form 4 |
| Dec 9, 2025 | Abbas Hussain | Director | Sale plan | 504 | $27.60 | $13.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Stephen Hoge | President | – | $45.4M | Oct 15, 2026 |
| Stephane Bancel | Chief Executive Officer, Director | – | $28.7M | Aug 5, 2026 |
| James M Mock | Chief Financial Officer | – | $4.7M | Sep 10, 2026 |
| Shannon Thyme Klinger | Chief Legal Officer | – | $1.4M | Sep 1, 2026 |
| Noubar Afeyan | Director | – | $1.1M | May 21, 2026 |
| Abbas Hussain | Director | – | $279K | May 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MRNA short interest
Moderate short interest. 8.2% of MRNA shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 43%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 33.19M MRNA shares were sold short, 8.2% of the shares outstanding, up 1.8% from the report before. At the average daily volume of 18.84M shares, buying them all back would take about 1.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 33.19M | 8.20% | +2% | 18.84M | 1.8 |
| Oct 15, 2026 | 32.60M | 8.17% | +6% | 18.29M | 1.8 |
| Sep 30, 2026 | 30.86M | 7.73% | -6% | 16.89M | 1.8 |
| Sep 15, 2026 | 32.87M | 8.23% | -16% | 13.01M | 2.5 |
| Aug 31, 2026 | 39.15M | 9.81% | -26% | 50.16M | 1.0 |
| Aug 14, 2026 | 52.81M | 13.23% | +6% | 5.77M | 9.2 |
| Jul 31, 2026 | 49.77M | 12.47% | -5% | 4.87M | 10.2 |
| Jul 15, 2026 | 52.40M | 13.21% | -1% | 8.63M | 6.1 |
| Jun 30, 2026 | 53.19M | 13.40% | -9% | 11.53M | 4.6 |
| Jun 15, 2026 | 58.66M | 14.79% | +1% | 5.60M | 10.5 |
| May 29, 2026 | 57.81M | 14.57% | -0% | 4.71M | 12.3 |
| May 15, 2026 | 58.07M | 14.64% | -0% | 10.32M | 5.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded MRNA
Since Nov 17, 2024, 4 members of Congress reported 3 purchases and 4 sales of MRNA. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Oct 20, 2026, reported Nov 10, 2026.
Purchases 3Sales 4
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Oct 20, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Nov 10, 2026 | Report |
| Sep 24, 2026 | Maria Elvira Salazar (R-FL) | Partial sale | $1K–$15K | Self | Oct 7, 2026 | Report |
| Aug 19, 2026 | Maria Elvira Salazar (R-FL) | Partial sale | $1K–$15K | Self | Sep 9, 2026 | Report |
| Aug 19, 2026 | Maria Elvira Salazar (R-FL) | Purchase | $1K–$15K | Self | Sep 9, 2026 | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Self | May 8, 2025 | Report |
| Feb 25, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $1K–$15K | Self | Mar 27, 2025 | Report |
| Jan 15, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | Feb 12, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Moderna company events
Moderna filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 6, 2026.
- Nov 6, 2026ResultsReleased financial results. Filing
- Sep 30, 2026LeadershipModerna, Inc. announced the appointment of Juan Andres as its Chief Operating Officer effective October 5, 2026. Filing
- Sep 1, 2026AgreementModerna, Inc. completed its previously announced private offering of $3 billion of 0.00% Convertible Senior Notes due 2032, including the exercise in full of the initial purchasers’ option to purchase up to an additional $400 million of the Notes. Filing
- Jul 31, 2026ResultsReleased financial results. Filing
- Jul 8, 2026LeadershipThe Board of Directors of Moderna, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Michael McDonnell to the Board, effective July 8, 2026. Filing
- May 11, 2026VoteReported shareholder vote results. Filing
- May 1, 2026ResultsReleased financial results. Filing
- Mar 5, 2026AgreementModerna, Inc. and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation, Genevant Sciences GmbH, and, solely for certain purposes, Genevant Sciences Ltd., entered into a settlement agreement to resolve all patent infringement litigation between Moderna and… Filing
- Feb 13, 2026ResultsReleased financial results. Filing
- Feb 11, 2026AnnouncementThe FDA's Center for Biologics Evaluation and Research notified the Company that it will not initiate a review of the biologics license application for the Company's investigational influenza vaccine, mRNA-1010, and has issued a Refusal-to-File letter. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Jan 5, 2026AnnouncementShared information with investors. Filing
- Nov 24, 2025AgreementModerna, Inc. entered into a Credit and Guaranty Agreement, among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent. Filing
- Nov 20, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Moderna financials
Famous investors that hold MRNA
5 of the 50 well-known investors we track reported holding MRNA in their latest 13F filing. The largest position is Israel Englander's, worth $750M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 3.89M | $750M | 0.6% | +788% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 116,160 | $22.4M | 0.0% | -61% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 108,615 | $20.9M | 0.0% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 72,342 | $13.9M | 0.1% | +528% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 9,154 | $1.8M | 0.0% | -16% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MRNA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 14.8% |
| Nov 5, 2026 | FMR LLC | 13G/A | 14.8% |
Questions about Moderna, Inc. (MRNA) stock
Who owns the most MRNA stock?
The largest reported owner of Moderna, Inc. (MRNA) is FMR LLC (Fidelity), with 13.1% of the company. In total, 776 funds and institutions reported holding MRNA at the end of Q2 2026, together about 81% of the shares. See the largest owners.
Are MRNA insiders buying or selling?
In the last 12 months, MRNA insiders reported no open-market purchases and 22 sales worth $81.6M. The latest trade was on Oct 15, 2026. See every trade.
What is the short interest in MRNA?
As of Oct 30, 2026, 33.19M MRNA shares were sold short, 8.2% of the shares outstanding, up 1.8% from the report before. At the average daily volume of 18.84M shares, buying them all back would take about 1.8 trading days (days to cover). See the history.
Have members of Congress traded MRNA?
Yes. 4 members of Congress reported 3 purchases and 4 sales of MRNA since Nov 17, 2024. The latest was reported on Nov 10, 2026. See the trades.
Which famous investors hold MRNA?
5 of the 50 well-known investors we track reported MRNA in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $750M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.